11β-hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction

Endocrine Journal

Volumn 60, Issue 9, 2013, Pages 1047-1058

  Wu, Lin ^a   Qi, Hanmei ^a   Zhong, Yi ^b   Lv, Shan ^a   Yu, Jing ^a   Liu, Juan ^a   Wang, Long ^c   Bi, Jianhua ^a   Kong, Xiaocen ^a   Di, Wenjuan ^a   Zha, Juanmin ^a   Liu, Feng ^a   Ding, Guoxian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

11 hydroxysteroid dehydrogenase type 1; BVT.2733; Lentivirus; MC3T3 E1 preosteoblast; Senile osteoporosis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; ALKALINE PHOSPHATASE BONE ISOENZYME; BONE SIALOPROTEIN; CALCIUM; CORTICOSTERONE; DEHYDROCORTICOSTERONE; DEXAMETHASONE; GLUCOCORTICOID; LENTIVIRUS VECTOR; MESSENGER RNA; MIFEPRISTONE; OSTEOCALCIN; OSTEOPONTIN;

ALP GENE; ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BSP GENE; CELL DIFFERENTIATION; CELL PROTECTION; CONTROLLED STUDY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; INHIBITION KINETICS; MOUSE; NONHUMAN; OCN GENE; OPN GENE; OSTEOBLAST; SENILE OSTEOPOROSIS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3T3-L1 CELLS; ANIMALS; ANIMALS, NEWBORN; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; CORTICOSTERONE; DEXAMETHASONE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; HORMONE ANTAGONISTS; MICE; OSTEOBLASTS; OSTEOGENESIS; PIPERAZINES; RECEPTORS, GLUCOCORTICOID; RECOMBINANT PROTEINS; SKULL; SULFONAMIDES; THIAZOLES;

EID: 84884944010     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0376     Document Type: Article

References (26)

1. Dempster DW (1989) Bone histomorphometry in glu-cocorticoid-induced osteoporosis. J Bone Miner Res 4: 137-141.
2. Advani S, LaFrancis D, Bogdanovic E, Taxel P, Raisz LG, et al. (1997) Dexamethasone suppresses in vivo levels of bone collagen synthesis in neonatal mice. Bone 20: 41-46.
3. Buttgereit F, Burmester GR, Lipworth BJ (2005) Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 365: 801-803.
4. De Nijs RN (2008) Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med 99: 23-43.
5. Cooper MS (2008) 11beta-Hydroxysteroid dehydroge-nase: a regulator of glucocorticoid response in osteoporosis. J Endocrinol Invest 31 (7 Suppl): 16-21.
6. Pierotti S, Gandini L, Lenzi A, Isidori AM (2008) Pre-receptorial regulation of steroid hormones in bone cells: insights on glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 108: 292-299.
7. Chapman KE, Seckl JR (2008) 11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function. Neurochem Res 33: 624-636.
8. Alberts P, Engblom L, Edling N, Forsgren M, Klingström G, et al. (2002) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45: 1528-1532.
9. Barf T, Vallgårda J, Emond R, Haggstrom C, Kurz G, et al. (2002) Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1. J Med Chem 45: 3813-3815.
10. Wang SJY, Birtles S, Schoolmeester J, Swales J, Moody G, et al. (2006) Inhibition of 11β-hydroxysteroid dehy-drogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 49: 1333-1337.
11. Alberts P, Nilsson C, Selén G, Engblom LOM, Edling NHM, et al. (2003) Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains. Endocrinology 144: 4755-4762.
12. Emira A, Carlo R (2009) Glucocorticoid-induced leu-cine zipper (GILZ): a new important mediator of gluco-corticoid action. FASEB J 23: 3649-3658.
13. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, et al. (2002) Osteoblastic 11beta-hydrox-ysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17: 979-986.
14. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, et al. (1997) 11beta-hydroxysteroid dehy-drogenase type 1 knockout mice show attenuated gluco-corticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci 94: 14924-14929.
15. Justesen J, Mosekilde L, Holmes M, Stenderup K, Gasser J, et al. (2004) Mice deficient in 11beta-hy-droxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology 145: 1916-1925.
16. White PC, Mune T, Agarwal AK (1997) 11 beta-Hy-droxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18: 135-156.
17. Bakker AD, Klein-Nulend J (2003) Osteoblast Isolation from Murine Calvariae and Long Bones. Methods Mol Med 816: 19-28.
18. Bellows CG, Aubin JE, Heersche JN (1987) Physiological concentrations of glucocorticoids stimulate formation of bone nodules from isolated rat calvaria cells in vitro. Endocrinology 121: 1985-1992.
19. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I (1994) Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dex-amethasone and BMP-2. Dev Biol 161: 218-228.
20. Eijken M, Koedam M, van Driel M, Buurman CJ, Pols HA, et al. (2006) The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Mol Cell Endocrinol 248: 87-93.
21. Pereira RM, Delany AM, Canalis E (2001) Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28: 484-490.
22. Luppen CA, Smith E, Spevak L, Boskey AL, Frenkel B (2003) Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteo-blast cultures. J Bone Miner Res 18: 1186-1197.
23. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL (2008) Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149: 1793-1801.
24. Lien CY, Chih-Yuan Ho K, Lee OK, Blunn GW, Su Y (2009) Restoration of bone mass and strength in glu-cocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 co-expressing mesenchymal stem cells. J Bone Miner Res 24: 837-848.
25. Li H, Qian W, Weng X, Wu Z, Li H, et al. (2012) Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells. PLoS One 7: e37030.
26. Cohen PG (2005) Estradiol induced inhibition of 11beta-hydroxysteroid dehydrogenase 1: an explanation for the postmenopausal hormone replacement therapy effects. Med Hypotheses 64: 989-991.